Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-lung 8 trial

by on 20 de setembre de 2021 with No hi ha comentaris
  • Goss, G. D., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., . . . Felip, E. (2021). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-lung 8 trial. EClinicalMedicine, 37. https://doi.org/10.1016/j.eclinm.2021.100940

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *